Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomonas aeruginosa from Cystic Fibrosis Patients
- 25 February 2015
- journal article
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 28 (5) , 353-360
Abstract
Background: The rise in antibiotic-resistant Pseudomonas aeruginosa and the considerable difficulty in eradicating it from patients has re-motivated the study of bacteriophages as a therapeutic option. For this to be effective, host range and viability following nebulization need to be assessed. Host-range has not previously been assessed for the Liverpool Epidemic Strain (LES) isolates that are the most common cystic fibrosis-related clone of P. aeruginosa in the UK. Nebulization studies have not previously been linked to clinically relevant phages. Methods: 84 phenotypically variable isolates of the LES were tested for susceptibility to seven bacteriophages known to have activity against P. aeruginosa . Five of the phages were from the Eliava Institute (IBMV) and 2 were isolated in this study. The viability of the two bacteriophages with the largest host ranges was characterized further to determine their ability to be nebulized and delivered to the lower airways. Phages were nebulized into a cascade impactor and the phage concentration was measured. Results: The bacteriophages tested killed between 66%–98% of the 84 Liverpool Epidemic Strain isolates. Two isolates were multi phage resistant, but were sensitive to most first line anti-Pseudomonal antibiotics. The amount of viable bacteriophages contained in particles that are likely to reach the lower airways (P. aeruginosa bacteriophages can lyse up to 98% of 84 phenotypically diverse LES strains. High titers of phages can be effectively nebulized.Keywords
This publication has 48 references indexed in Scilit:
- The Susceptibility of Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients to BacteriophagesPLOS ONE, 2013
- Phenotypic Heterogeneity of Pseudomonas aeruginosa Populations in a Cystic Fibrosis PatientPLOS ONE, 2013
- Effects of Sequential and Simultaneous Applications of Bacteriophages on Populations of Pseudomonas aeruginosa In Vitro and in Wax Moth LarvaeApplied and Environmental Microbiology, 2012
- Bacteriophages ϕMR299-2 and ϕNH-4 Can Eliminate Pseudomonas aeruginosa in the Murine Lung and on Cystic Fibrosis Lung Airway CellsmBio, 2012
- Pseudomonas aeruginosa Population Diversity and Turnover in Cystic Fibrosis Chronic InfectionsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Pulmonary Bacteriophage Therapy on Pseudomonas aeruginosa Cystic Fibrosis Strains: First Steps Towards Treatment and PreventionPLOS ONE, 2011
- Fluctuations in phenotypes and genotypes within populations of Pseudomonasaeruginosa in the cystic fibrosis lung during pulmonary exacerbationsJournal of Medical Microbiology, 2010
- Quality-Controlled Small-Scale Production of a Well-Defined Bacteriophage Cocktail for Use in Human Clinical TrialsPLOS ONE, 2009
- Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosaGenome Research, 2008
- Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in MiceAntimicrobial Agents and Chemotherapy, 2007